PhRMA | Behind the 340B Drug Pricing Program

Perspectives on the 340B Drug Pricing Program | The U.S. Senate Committee on Health, Education, Labor & Pensions

Oversight and Investigations Subcommittee Hearing: “Oversight of 340B Drug Pricing Program”

CBO report: 340B increases federal spending, but saves HIV patients | Sid Viswanathan posted on the topic | LinkedIn

Omnicell 340B | Omnicell

340B Pharmacy Program Coordinator Remote

The federal 340B program requires drug makers to sell their products to some hospitals at a discount. Hospitals and contract pharmacies can then resell them and pocket the difference. It’s a case of the government picking winners (hospitals) and losers (drug manufacturers) among private market participants. Hospitals argue that they need the money to help patients. That is, they use the extra revenue from the program to cut costs or provide free care for those in need. But Jarrett Skorup of the

The 340B Drug Pricing Program

11 reactions | Taxpayers are footing the bill for the 340B Drug Pricing Program. Hospitals, contract pharmacies, and special interest sharks are profiting. They’re taking advantage of 340B discounts meant for patients, and it’s costing taxpayers. We can fix the mess if Congress reforms the program. https://www.cagw.org/340B #Fix340B | Citizens Against Government Waste | Facebook